On February 2, 2018, WLF filed a brief in the U.S. Supreme Court, urging it to review (and ultimately overturn) an appeals court decision that authorizes private individuals to sue pharmaceutical manufacturers for government-contracting fraud based on technical violations of federal regulations—even if the FDA approved the drugs and government officials continued to purchase them after investigating the fraud allegations. WLF argued that the appeals court’s decision conflicts with Supreme Court precedent and facilitates the filing of unwarranted fraud claims under the False Claims Act (FCA) against government contractors. The plaintiff’s fraud claims were investigated by government officials. They ultimately took no action; the drugs remained FDA-approved, and the government continues to purchase billions of dollars of the drugs each year. WLF argued that that response demonstrates that the FCA claim must be dismissed because any regulatory violation was not “material.”